TruScreen Commences Large Scale Chinese Pilot with CDC

25 July 2018
NZX Announcement

TruScreen Commences Large Scale Chinese Pilot with CDC

Cervical cancer technology company, TruScreen Limited (NZAX:TRU), announces that it has now
commenced the large scale Chinese evaluation (previously advised) with The Women’s and
Children’s Division of the Centre for Disease Control (CDC) .
The aim of the evaluation is multifold: To have TruScreen included in the CDC’s screening guidelines
for the 3000 hospitals run by its Women’s and Children’s Health Division; to have the CDC
recommend TruScreen for inclusion in the Central Government’s Ministry of Health screening
guidelines for all 12,000 government hospitals in China; and, as part of the evaluation, TruScreen will
also be assessed for use as a first choice screening technology in rural areas in China.
The evaluation will involve a minimum of 12,000 women across eight provinces and 16 hospitals in
China is expected to generate $162,000 revenue for TruScreen during the next three months.
Chairman of TruScreen, Robert Hunter, said: “we are extremely confident of TruScreen’s Clinical
capabilities and this pilot program is an essential component to gaining acceptance by the Chinese
national healthcare administrators and for inclusion in the National Cervical Screening guidelines.
When complete, this endorsement will be the key to TruScreen gaining access to over 3,000
hospitals and a share of the 10 million Central Government funded screening tests conducted in
these hospitals each year.”
The CDC is responsible for conducting Central Government sponsored screening programs in China,
for cervical cancers, through its hospitals and the Central Government Ministry of Health directly
funds these 10 million cervical cancer screening tests per year through CDC hospitals, which is a
market valued in excess of $75 million per annum.

With 400 million women of screening age, China remains our primary market opportunity and we
have experienced significant increase in sales since CFDA approval was received at the end of 2017.


ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.